Journal
CANCER CELL
Volume 18, Issue 6, Pages 641-654Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2010.10.028
Keywords
-
Categories
Funding
- Ministerio de Ciencia e Innovacion (MICINN) [SAF2009-07973, CSD2007-00017]
- Marie Curie Cancer Care
- Association for International Cancer Research (AICR)
- Fundacion Cientifica de la Asociacion Espanola contra el Cancer
- Junta de Castilla y Leon Grupo de Excelencia [GP 265]
- Comunidad de Madrid [S-BIO-0283-2006]
- Fundacion Ramon Areces, AICR [08-0188]
- European Union [HEALTH-F5-2010-241548]
- [BFU2008-01808]
- [CSD2007-00015]
- Worldwide Cancer Research [09-0658] Funding Source: researchfish
Ask authors/readers for more resources
Targeting mitotic exit has been recently proposed as a relevant therapeutic approach against cancer. By using genetically engineered mice, we show that the APC/C cofactor Cdc20 is essential for anaphase onset in vivo in embryonic or adult cells, including progenitor/stem cells. Ablation of Cdc20 results in efficient regression of aggressive tumors, whereas current mitotic drugs display limited effects. Yet, Cdc20 null cells can exit from mitosis upon inactivation of Cdk1 and the kinase Mastl (Greatwall). This mitotic exit depends on the activity of PP2A phosphatase complexes containing B55 alpha or B55 delta regulatory subunits. These data illustrate the relevance of critical players of mitotic exit in mammals and their implications in the balance between cell death and mitotic exit in tumor cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available